Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-0796 in Obese Participants With/Without Type 2 Diabetes
NCT07055516Phase 2Completed
- Sponsor
- Rezera
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruvonoflast in obesity, type 2 diabetes mellitus (T2DM), sponsored by Rezera. Started May 2025; status: completed.
02
Drugs
ruvonoflast
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07055516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055516.